These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33211989)

  • 1. Repeated prolonged moderate-intensity walking exercise does not appear to have harmful effects on inflammatory markers in patients with inflammatory bowel disease.
    Lamers CR; de Roos NM; Bongers CCWG; Ten Haaf DSM; Hartman YAW; Witteman BJM; Hopman MTE
    Scand J Gastroenterol; 2021 Jan; 56(1):30-37. PubMed ID: 33211989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IBD-FITT study - moderate-intensity exercise for patients with inflammatory bowel disease with moderate disease activity: an open-label randomized controlled trial.
    Lund K; Knudsen T; Kjeldsen J; Nielsen RG; Juhl CB; Nørgård BM
    Trials; 2023 Nov; 24(1):742. PubMed ID: 37986021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
    Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
    Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
    Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease.
    Shentova R; Baycheva M; Kofinova D; Hadjiiski P; Yaneva P
    Folia Med (Plovdiv); 2020 Jun; 62(2):271-275. PubMed ID: 32666743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
    Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
    Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease.
    Gauss A; Geiss T; Hinz U; Schaefert R; Zwickel P; Zawierucha A; Stremmel W; Klute L
    Medicine (Baltimore); 2016 Apr; 95(16):e3477. PubMed ID: 27100452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an extract based on the medicinal mushroom Agaricus blazei Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn's disease.
    Førland DT; Johnson E; Saetre L; Lyberg T; Lygren I; Hetland G
    Scand J Immunol; 2011 Jan; 73(1):66-75. PubMed ID: 21129005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?
    Boon GJ; Day AS; Mulder CJ; Gearry RB
    World J Gastroenterol; 2015 Oct; 21(40):11469-80. PubMed ID: 26523111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.
    Rosenfeld G; Greenup AJ; Round A; Takach O; Halparin L; Saadeddin A; Ho JK; Lee T; Enns R; Bressler B
    World J Gastroenterol; 2016 Sep; 22(36):8211-8. PubMed ID: 27688663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Eur J Clin Invest; 2016 Oct; 46(10):825-32. PubMed ID: 27438629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refractory neutrophils and monocytes in patients with inflammatory bowel disease after repeated bouts of prolonged exercise.
    Spijkerman R; Hesselink L; Bertinetto C; Bongers CCWG; Hietbrink F; Vrisekoop N; Leenen LPH; Hopman MTE; Jansen JJ; Koenderman L
    Cytometry B Clin Cytom; 2021 Nov; 100(6):676-682. PubMed ID: 33683008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
    Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of faecal inflammatory marker concentration as a noninvasive method of evaluation of pathological activity in children with inflammatory bowel diseases.
    Roszak D; Gałęcka M; Cichy W; Szachta P
    Adv Med Sci; 2015 Sep; 60(2):246-52. PubMed ID: 25989184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
    J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease.
    Burri E; Beglinger C
    Swiss Med Wkly; 2012; 142():w13557. PubMed ID: 22481443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of serum calprotectin in assessing inflammatory bowel disease activity].
    Mao JY; Li L; Pang Z
    Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):3001-3004. PubMed ID: 29061007
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.